Last reviewed · How we verify
GSK1349572 and MaaloxAdvanced Maximum Strength — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK1349572 and MaaloxAdvanced Maximum Strength (GSK1349572 and MaaloxAdvanced Maximum Strength) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK1349572 and MaaloxAdvanced Maximum Strength TARGET | GSK1349572 and MaaloxAdvanced Maximum Strength | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK1349572 and MaaloxAdvanced Maximum Strength CI watch — RSS
- GSK1349572 and MaaloxAdvanced Maximum Strength CI watch — Atom
- GSK1349572 and MaaloxAdvanced Maximum Strength CI watch — JSON
- GSK1349572 and MaaloxAdvanced Maximum Strength alone — RSS
Cite this brief
Drug Landscape (2026). GSK1349572 and MaaloxAdvanced Maximum Strength — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1349572-and-maaloxadvanced-maximum-strength. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab